Current treatment management of metastatatic castration-resistant prostate cancer

Article Properties
  • DOI (url)
    10.36290/xon.2017.038
  • Publication Date
    2017/10/01
  • Journal
    Onkologie
  • Indian UGC (journal)
  • Refrences
    18
  • Citations
    1
  • Nikol Rušarová
  • Hana Študentová
Cite
Rušarová, Nikol, and Hana Študentová. “Current Treatment Management of Metastatatic Castration-Resistant Prostate Cancer”. Onkologie, vol. 11, no. 4, 2017, pp. 200-4, https://doi.org/10.36290/xon.2017.038.
Rušarová, N., & Študentová, H. (2017). Current treatment management of metastatatic castration-resistant prostate cancer. Onkologie, 11(4), 200-204. https://doi.org/10.36290/xon.2017.038
Rušarová, Nikol, and Hana Študentová. “Current Treatment Management of Metastatatic Castration-Resistant Prostate Cancer”. Onkologie 11, no. 4 (2017): 200-204. https://doi.org/10.36290/xon.2017.038.
Rušarová N, Študentová H. Current treatment management of metastatatic castration-resistant prostate cancer. Onkologie. 2017;11(4):200-4.
Refrences
Title Journal Journal Categories Citations Publication Date
10.1016/S0140-6736(10)61389-X
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial European Journal of Cancer
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
 54 2016
10.1111/j.1464-410X.2010.09498.x
10.1056/NEJMoa041318
10.1200/JCO.2007.12.4008
Citations
Title Journal Journal Categories Citations Publication Date
Enzalutamide in treatment of the metastatic castrate resistant prostate cancer Onkologie 2019
Citations Analysis
The first research to cite this article was titled Enzalutamide in treatment of the metastatic castrate resistant prostate cancer and was published in 2019. The most recent citation comes from a 2019 study titled Enzalutamide in treatment of the metastatic castrate resistant prostate cancer. This article reached its peak citation in 2019, with 1 citations. It has been cited in 1 different journals. Among related journals, the Onkologie cited this research the most, with 1 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year